FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GREENLEAF DANIEL E 		2. Issuer Name and Ticker or Trading Symbol

BioScrip, Inc. [ BIOS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O BIOSCRIP, INC., 1600 BROADWAY, SUITE 700 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/18/2019
(Street)

DENVER, CO 80202
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.0001 Par Value   4/18/2019   (1)   M    136185   A $0   (2) 209881   D    
Common Stock, $.0001 Par Value   4/18/2019   (3)   M    98425   A $0   (2) 308306   D    
Common Stock, $.0001 Par Value   4/18/2019     D    67994   D $1.82   (4) 240312   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit     (5) 4/18/2019   (1)   M         136185      (5) 12/31/2019   Common Stock, $.0001 Par Value   136185     (2) 0   (6) D    
Restricted Stock Unit     (2) 4/18/2019   (3)   M         98425      (7)   (7) Common Stock, $.0001 Par Value   98425     (2) 196850   D    

Explanation of Responses:
(1)  136,185 Restricted Stock Units (RSUs) vested in January 2019 based on the satisfaction of certain Company stock price trading targets; however, as provided in the grant agreement, the Company deferred settlement of the 136,185 RSUs until April 18, 2019
(2)  Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock.
(3)  One third (98,425 RSUs) of Mr. Greenleaf's original award of 295,275 RSUs vested on the first anniversary of the original grant date (April 11, 2018); however, as provided in the grant agreement, the Company deferred settlement of the 98,425 RSUs until April 18, 2019.
(4)  This transaction represents shares withheld by the Company for tax withholding on Mr. Greenleaf's settlement of the two RSU awards described in this Form 4 that were settled on April 18, 2019.
(5)  Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Vesting occurs if Company stock price, as measured by 20-day average stock price ending December 31, 2019, reaches specified levels.
(6)  Depending on Company stock price at the end of the performance period, payout may be 0, 50, 100 or 200% of reported amount.
(7)  The remaining 196,850 RSUs vest in two equal installments commencing on the second and third anniversaries of the date of grant (4/11/2018).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GREENLEAF DANIEL E
C/O BIOSCRIP, INC.
1600 BROADWAY, SUITE 700
DENVER, CO 80202

Chief Executive Officer

Signatures
/s/ Daniel E. Greenleaf 4/22/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioPlus Acquisition Charts.
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioPlus Acquisition Charts.